FDA clears IND application for ERAS-4001 for the treatment of patients with KRAS-mutant (KRASm) solid tumors
“Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “ERAS-4001 targets multiple KRAS mutations as well as wildtype KRAS but spares HRAS and NRAS, potentially enabling a better therapeutic window relative to pan-RAS inhibitors. We believe these attributes offer a differentiated approach that can overcome treatment resistance to pan-RAS and mutant-selective KRAS inhibitors and address unmet needs for the 2.2 million people diagnosed annually worldwide with KRASm tumors. We look forward to continued efficient execution across our RAS-targeting programs and anticipate disclosing initial monotherapy data in 2026.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines